Glucagon and GLP-1 impact on glucose control, food intake, and hepatic protein and lipid metabolism [1], and co-agonists of these two hormones are being tested in clinical trials for the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [2, 3]. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.